NCT04184050View on ClinicalTrials.gov

Study of HPN217 in Participants With Relapsed/Refractory Multiple Myeloma MK-4002 (MK-4002-001)

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

April 13, 2020

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2026

Conditions
Multiple Myeloma in RelapseMultiple MyelomaMultiple Myeloma of BoneMultiple Myeloma With Failed Remission
Interventions
DRUG

MK-4002

IV infusion

Trial Locations (12)

14263

Roswell Park Comprehensive Cancer Center, Buffalo

14642

University of Rochester James P Wilmot Cancer Institute, Rochester

28040

Hospital Universitario Fundacion Jimenez Diaz (UAM-FJD), Madrid

44093

Centre Hospitalier Universitaire De Nantes, Nantes

66205

The University of Kansas Cancer Center, Fairway

85054

Mayo Clinic Arizona, Phoenix

85234

Banner MD Anderson Cancer Center, Gilbert

86021

Centre Hospitalier Universitaire de Poitiers, Poitiers

92093

UC San Diego Moores Cancer Center, La Jolla

97239

OHSU, Portland

98109

University of Washington - Seattle Cancer Center Alliance, Seattle

08916

Josep Carreras Leukaemia Research Institute, Barcelona

All Listed Sponsors
lead

Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

INDUSTRY